scholarly journals Short-Term Cost-Effectiveness of Glucagon-Like Peptide-1 Receptor Analogues Versus Sodium-Glucose Cotransporter-2 Inhibitors as Second-Line Add-On Therapy for Type 2 Diabetes in the United States

2018 ◽  
Vol 21 ◽  
pp. S75
Author(s):  
N Ruiz-Negron ◽  
J Menon ◽  
BK Bellows
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
The United States ◽  
Second Line ◽  
Short Term ◽  
Sodium Glucose Cotransporter ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1158-P
Author(s):  
ODETTE REIFSNIDER ◽  
PRATIK PIMPLE ◽  
MATTHEW J.D. STARGARDTER ◽  
SARAH BRAND ◽  
NIHAR DESAI ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
The United States ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States

2021 ◽  
Author(s):  
Odette S. Reifsnider ◽  
Pratik Pimple ◽  
Sarah Brand ◽  
Evelien Bergrath Washington ◽  
Sharash Shetty ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
The United States ◽  
Second Line
Sign in / Sign up

Export Citation Format

Share Document